Atopic Dermatitis
Conditions
Interventions
Treatment Group:Pour the formula granules of nourishing yin and dehumidifying soup into a container, add an appropriate amount of hot water, stir and mix well, and take it warm, 2 times a day. Apply a
Control Group:Control group: Pour the simulant formula granules into a container, add an appropriate amount of hot water, stir and mix well, and take it warm, twice a day. Apply an appropriate amount
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1 Meet the Chinese AD diagnostic criteria proposed by ZHANG Jian-zhong in the "Chinese Guidelines for the Diagnosis and Treatment of Atopic Dermatitis"; 2 Age 18 to 70 (including 18 and 70); 3 SCORAD score of 25 to 50 (including 25 and 50); 4 Meet the diagnostic criteria of "Yin Deficiency and Damp Love Syndrome" in traditional Chinese medicine; 5 Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1 Patients with any other systemic or active skin diseases (such as acute allergic dermatitis, psoriasis, lupus erythematosus) that may affect the evaluation of the test results; or have scars, tattoos, birthmarks or other pigments at the skin lesions Patients with sexual dermatosis, etc., which can affect the evaluation of skin lesions; 2. Patients with serious primary diseases such as heart, cerebrovascular, liver, kidney, gastrointestinal tract, hematopoietic system, endocrine, etc., as well as patients with mental diseases; 3. Pregnant, lactating women and those who are about to become pregnant in the past 3 months; 4. Patients who have used biological agents within 28 days before treatment; patients who have systematically used antihistamines, glucocorticoids, immunosuppressants and other therapeutic drugs within 14 days before treatment; or topical glucocorticoids and calcineurin within 7 days before treatment Patients with therapeutic drugs such as inhibitors; 5 Those who are participating in other clinical trials during the trial observation period; 6 Those who are allergic to the drug in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scoring Atopic Dermatitis Index (SCORAD); | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM symptom/sign record;Dermatology Life Quality Index (DLQI); | — |
Countries
China
Contacts
Public ContactSHEN Dong
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed